Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
2017 · Nature Medicine · 3,415 citations
https://doi.org/10.1038/nm.4333
J
James J. Harding
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
542
Papers
17.5K
Citations
53
h-index
128
i10-index
James J. Harding is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cholangiocarcinoma and Gallbladder Cancer Studies & Cancer Genomics and Diagnostics & Hepatocellular Carcinoma Treatment and Prognosis. The author has an h-index of 53, co-authored 461 publications.
ORCID: 0000-0002-7029-4310Papers by this author
worksHER kinase inhibition in patients with HER2- and HER3-mutant cancers
2018 · Nature · 769 citations
https://doi.org/10.1038/nature25475
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
2018 · Annals of Oncology · 243 citations
https://doi.org/10.1093/annonc/mdy101
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
2023 · The Lancet Oncology · 201 citations
https://doi.org/10.1016/s1470-2045(23)00242-5
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
2021 · Nature Communications · 176 citations
https://doi.org/10.1038/s41467-021-24109-5
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
2023 · Nature Communications · 76 citations
https://doi.org/10.1038/s41467-023-36399-y
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat